Insights/social_linkedin/Complaint trends are rising for one product family but you can't tell if it's an industry-wide issue or yours alone. You're sifting through internal reports, trying to decide if this warrants a CAPA o
social_linkedin

Complaint trends are rising for one product family but you can't tell if it's an industry-wide issue or yours alone. You're sifting through internal reports, trying to decide if this warrants a CAPA o

By TrueMedDevice TeamMarch 1, 20262 min read

Here's what's happening right now: 391 new FDA recalls were issued this week, with a significant cluster in convenience kits used for dialysis maintenance, including specific SKUs like Medline's ADD A CATH DIALYSIS KIT ECVC8415A and Centurion's CENTRAL LINE INSERTION TRAY DT19810. These recalls cite issues like silicone seal failures leading to occluded fluid paths, which could delay therapy or cause leaks. Additionally, there are 26,000 new FDA Adverse Event Reports (MAUDE/MDRs), with notable signals in insulin pumps and continuous glucose monitors, such as injuries reported for Beta Bionics' iLet Bionic Pancreas and malfunctions for Dexcom's G6 system.

For QA Engineers focused on CAPA prioritization and root cause analysis under 21 CFR 820.90 and ISO 13485 8.5.2, this data highlights critical patterns. The dialysis kit recalls point to supplier quality and component nonconformance risks—silicone seal issues are a recurring failure mode that may require enhanced incoming inspection or supplier audits. Meanwhile, the volume of adverse events in diabetes devices suggests broader industry challenges with software integration and performance, impacting complaint handling and nonconformance trending. Notice how labeling errors, as seen in orthopedic implants like the Reverse Shoulder Prosthesis, also tie back to process control gaps in your QMSR.

We analyzed this across 548,000+ regulatory records and found that such clusters often precede broader enforcement actions, making early signal detection key to proactive risk management.

See how your specific product codes compare to these emerging risks at truemeddevice.com.

Related Regulatory Signals

See how these signals relate to your device

Start a free pilot to match signals to your product portfolio automatically.

Start Pilot

Related Articles

social_linkedin

Management review is next week. ISO 13485 5.6 requires external signal data as input. Your team hasn't gathered it yet, and you're staring at a blank slide for the board report on risk exposure and co

Here's what's happening right now: There were 10,384 new regulatory signals today, including 10,360 FDA Adverse Event Reports (MAUDE/MDRs) and 22 Health Canada mdl entries. Notably, Health Canada issued 2 new recalls: Auro-Canagliflozin for incorrect DIN labeling and LUXA-D for a foreign product in a capsule, both flagged for product safety. For your management review under QMSR and 21 CFR 820, this data isn't just noise—it's critical for quantifying risk exposure and benchmarking against compe

April 4, 2026

social_linkedin

Complaint trends are rising for one product family but you can't tell if it's an industry-wide issue or yours alone. You're reviewing your CAPA dashboard, trying to prioritize investigations against l

Here's what's happening right now: 10,384 new regulatory signals hit the system today. That includes 10,360 new FDA adverse event reports (MAUDE/MDRs) and 2 new Health Canada recalls. One recall involves incorrect DIN labeling on a blister card (Auro-Canagliflozin), and another involves a foreign product in a capsule batch (LUXA-D). For your CAPA prioritization and complaint handling, notice the pattern in the MDRs: multiple reports for infusion set tubing detachment events and software/app mal

April 4, 2026

social_linkedin

A competitor's device just got recalled. Your auditor will ask: 'How did you evaluate whether this affects your products?' You're reviewing the alert, knowing it could trigger a supplier audit or requ

Here's what's happening right now: 2 new Health Canada recalls were issued this week, both for product safety issues. Auro-Canagliflozin has affected lots with incorrect DIN labeling on blister cards, and LUXA-D has a capsule containing a foreign product in the batch. This adds to 10,360 new FDA Adverse Event Reports (MAUDE/MDRs) and 22 new Health Canada mdl signals today, totaling 10,384 new regulatory signals. For RA Managers focused on audit preparedness and post-market surveillance, these s

April 4, 2026

Social — QA Engineer — Mar 01, 2026 | TrueMedDevice